Extractions of Medical Cannabis Cultivars and the Role of Decarboxylation in Optimal Receptor Responses.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 101684827 Publication Model: eCollection Cited Medium: Print ISSN: 2578-5125 (Print) Linking ISSN: 23788763 NLM ISO Abbreviation: Cannabis Cannabinoid Res Subsets: PubMed not MEDLINE
    • Publication Information:
      Original Publication: New Rochelle, NY : Mary Ann Liebert, Inc., [2016]-
    • Abstract:
      Introduction: Phytocannabinoids, characteristic compounds produced by medical cannabis, interact with cannabinoid (CB) receptors (CB1 and CB2) as well as other receptor systems to exhibit their corresponding pharmacological effects. In their natural form, CBs such as Δ 9 -tetrahydrocannabinolic acid and cannabidiolic acid are inactive at these receptors, while their decarboxylated forms (Δ 9 -tetrahydrocannabinol and cannabidiol, respectively) are potent ligands at CB receptors. Thus, extraction and processing of medical cannabis for active constituents are important. Purpose and Methods: Patients consuming medical cannabis often have limited alternative treatment options and in recent years, medical cannabis extracts have been popular as a substitute for dried cannabis plants, despite limited studies on these derivatives. We investigated three disparate cannabis cultivars and compared four chemical extraction methods head to head, viz. Soxhlet, ultrasound-assisted supercritical fluid, and microwave-assisted extractions, for their efficiency. We further characterized the chemical compositions of these extracts. Results: Microwave extraction consistently produced completely decarboxylated phytocannabinoid extracts. Factors such as temperature and exposure time play important roles in the decarboxylation of phytocannabinoids, thereby generating pharmacologically active CBs, and these conditions may differ for each cannabis cultivar. Conclusion: Chemical consistency and potency due to active compounds are in turn important in producing consistent and reliable medical cannabis extracts and their derivatives. These processes must be subject to higher levels of scientific rigor as the patient population around the world are seeking the help of such extracts for various clinical conditions, and as medical cannabis industry is receiving acceptance in various countries.
    • References:
      J Pharmacol Exp Ther. 2001 Feb;296(2):420-5. (PMID: 11160626)
      Br J Pharmacol. 2001 Oct;134(4):845-52. (PMID: 11606325)
      Eur J Pharmacol. 2004 Mar 8;487(1-3):213-21. (PMID: 15033394)
      Drug Dev Ind Pharm. 2006 Jan;32(1):21-32. (PMID: 16455601)
      Br J Pharmacol. 2007 Mar;150(5):613-23. (PMID: 17245363)
      Br J Pharmacol. 2008 Jan;153(2):199-215. (PMID: 17828291)
      J Biol Chem. 2008 Dec 12;283(50):34643-9. (PMID: 18854305)
      Pharmacol Rev. 2010 Dec;62(4):588-631. (PMID: 21079038)
      J Forensic Sci. 2012 Jul;57(4):918-22. (PMID: 22390363)
      Prostaglandins Other Lipid Mediat. 2013 Apr-May;102-103:13-30. (PMID: 23474290)
      J Sep Sci. 2013 Apr;36(8):1397-404. (PMID: 23505258)
      Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17165. (PMID: 24151330)
      J Food Sci Technol. 2015 Mar;52(3):1748-53. (PMID: 25745251)
      JAMA. 2015 Jun 23-30;313(24):2456-73. (PMID: 26103030)
      Nat Prod Rep. 2016 Nov 23;33(12):1357-1392. (PMID: 27722705)
      Biochem Pharmacol. 2017 Mar 15;128:1-11. (PMID: 27890725)
      Prog Chem Org Nat Prod. 2017;103:1-36. (PMID: 28120229)
      Epilepsy Behav. 2017 May;70(Pt B):341-348. (PMID: 28188044)
      Anal Bioanal Chem. 2017 May;409(12):3153-3163. (PMID: 28233028)
      N Engl J Med. 2017 May 25;376(21):2011-2020. (PMID: 28538134)
      J Pharm Biomed Anal. 2017 Sep 5;143:228-236. (PMID: 28609672)
      Cannabis Cannabinoid Res. 2017 May 01;2(1):87-95. (PMID: 28861508)
      Cannabis Cannabinoid Res. 2017 Oct 01;2(1):274-281. (PMID: 29098190)
      Molecules. 2017 Nov 03;22(11):null. (PMID: 29099795)
      Front Pharmacol. 2017 Oct 23;8:744. (PMID: 29109685)
      J Food Sci. 2018 Mar;83(3):700-710. (PMID: 29437231)
      Br J Pharmacol. 2019 May;176(10):1455-1469. (PMID: 29981240)
      ACS Omega. 2017 Sep 30;2(9):6091-6103. (PMID: 30023762)
      Experientia. 1972 Feb 15;28(2):121-2. (PMID: 5020324)
      Mol Pharmacol. 1995 Sep;48(3):443-50. (PMID: 7565624)
      FEBS Lett. 1994 Aug 22;350(2-3):240-4. (PMID: 8070571)
      J Biol Chem. 1996 Apr 26;271(17):9902-5. (PMID: 8626625)
      J Pharmacol Exp Ther. 1996 Sep;278(3):989-99. (PMID: 8819477)
      J Med Chem. 1997 Sep 26;40(20):3228-33. (PMID: 9379442)
    • Contributed Indexing:
      Keywords: cannabinoid receptors; decarboxylation; extraction; medical cannabis; phytocannabinoids
    • Publication Date:
      Date Created: 20190928 Latest Revision: 20201001
    • Publication Date:
      20220301
    • Accession Number:
      PMC6757234
    • Accession Number:
      10.1089/can.2018.0067
    • Accession Number:
      31559334